Bruce DeRenzi

I'll research this attorney's professional background and the tracked case.

Let me verify the tracked case and bar admissions.

Let me dig into the tracked case and notable Breckenridge matters.

Bruce D. DeRenzi — in-house IP/patent litigation counsel; VP, General Counsel & Head of Litigation, Breckenridge Pharmaceutical, Inc.

Focus areas. DeRenzi's patent work centers on pharmaceuticals and life sciences, with a background spanning the chemical, agrochemical, petroleum, printing, and mechanical arts. Firm-side practice descriptions from his time at Crowell & Moring emphasize chemical and pharmaceutical patent infringement litigation, opinions, and portfolio counseling. His in-house docket is dominated by Hatch-Waxman/ANDA-style pharmaceutical patent disputes rather than electronics, software, or standards-essential Wi-Fi work.

Side preference. The tracked data show a purely defense-side, in-house profile: 1 defendant-side appearance, 0 plaintiff-side. That reflects his role defending Breckenridge in patent litigation. It is not, however, a "pure defense" practice in the IPR sense — Breckenridge has itself filed or joined PTAB petitions as petitioner in ANDA-related challenges (see below), so he has exposure to both sides of a pharmaceutical patent fight, just from the branded/generic-adjacent company seat rather than an NPE/PAE plaintiff's seat.

Firm context. DeRenzi spent the first part of his career at Morgan & Finnegan LLP (associate, then partner), moved to Crowell & Moring as a partner when the Morgan & Finnegan group joined that firm, and then went in-house at Breckenridge Pharmaceutical, initially as litigation counsel and now as its chief legal officer and head of litigation. Date ranges for the Crowell-to-Breckenridge transition vary across third-party profile aggregators and could not be independently confirmed; court filings confirm he was acting for Breckenridge as of 2016.

Notable matters / PTAB experience. The single tracked appearance is Unified Patents, LLC v. Breckenridge Pharmaceutical Inc. (defendant, in-house); beyond the docket listing I could not verify further details of that proceeding, so its outcome should be treated as unconfirmed. Verifiable related activity includes Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc. (D. Del. 2016), where he was listed of counsel for Breckenridge; Pamlab, LLC v. Seton Pharmaceuticals, LLC (S.D.N.Y. 2010), a Cavan-X/folic acid product-disparagement dispute involving Breckenridge; and PTAB proceedings in which Breckenridge was a petitioner, including Breckenridge Pharmaceutical, Inc. v. Novartis AG, IPR2016-01023 (joined into IPR2016-00084), challenging U.S. Patent 5,665,772, which ended in a January 2018 final written decision upholding the claims. Breckenridge's joined-petitioner appeal in Mylan Pharmaceuticals Inc. v. Research Corp. Technologies, Inc. (Fed. Cir. Feb. 1, 2019) produced a notable appellate ruling that time-barred joined petitioners have standing to appeal; DeRenzi's personal role in that appeal is not documented. More recently, Breckenridge has been patent owner opposing institution in IPR2025-01107 (MSN Pharmaceuticals) on U.S. Patent 11,013,729 (dabigatran etexilate), parallel to Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc., No. 24-cv-571 (D. Del.). He appears principally as supervising in-house counsel in these PTAB matters, with outside firms on the briefs.

Bar / education. Third-party profiles list a B.S. in chemical engineering from Manhattan College and a J.D. from New York Law School, plus earlier work as a chemical process engineer at Colgate-Palmolive. These details come from aggregator sites rather than primary sources, and his bar admissions could not be independently verified — treat as unconfirmed.